|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100042106 |
|
最近更新日期: Date of Last Refreshed on: |
2021-01-14 09:23:56 |
|
注册时间: Date of Registration: |
2021-01-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
华西血浆指标研究 |
|
Public title: |
West China plasma indexes study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
肝素管和EDTA管对血浆指标的影响 |
|
Scientific title: |
The influence of Heparin tube and EDTA tube for plasma index |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
丁旭隆 |
研究负责人: |
雷鹏 |
|
Applicant: |
xulong-Ding |
Study leader: |
Peng Lei |
|
申请注册联系人电话: Applicant telephone: |
18956368797 |
研究负责人电话:
Study leader's |
19983138010 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
anhuijixidxl@163.com |
研究负责人电子邮件: Study leader's E-mail: |
peng.lei@scu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区人民南路三段17号 |
研究负责人通讯地址: |
四川省成都市武侯区人民南路三段17号 |
|
Applicant address: |
No.17 People's South Road,Chengdu |
Study leader's address: |
No.17 People's South Road,Chengdu |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学 |
||
|
Applicant's institution: |
Sichuan University |
||
|
研究负责人所在单位: |
四川大学 |
||
|
Affiliation of the Leader: |
Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2018 年 审 (116) 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
德阳市精神卫生中心医学伦理分委会 |
||
|
Name of the ethic committee: |
Ethics Committee of Mental health center of Deyang city |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2018-11-06 00:00:00 | ||
|
伦理委员会联系人: |
王文骁 |
||
|
Contact Name of the ethic committee: |
Wang wenxiao |
||
|
伦理委员会联系地址: |
德阳市华山南路二段461号 |
||
|
Contact Address of the ethic committee: |
No.461, Section 2, South Huashan Road, Deyang City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
0838-2872029 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Sichuan University |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区人民南路三段17号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No.17 People's South Road,Chengdu |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
四川大学华西医院卓越学科项目(ZY2016103,ZY2016203) |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Excellence program of West China Hospital, Sichuan University(ZY2016103,ZY2016203) |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
阿尔茨海默症 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Alzheimer's disease |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
测试使用不同的采血管(肝素和EDTA采血管)是否会改变高灵敏仪器检测出的血浆中的Tau,Abeta40 和 Abeta42蛋白的读数,以及这些指标是否与病人的认知相关 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
To test whether the value of plasma tau, Abeta40 and Abeta42 are altered when using heparin or EDTA tubes for blood collection and whether these indexes are related to the cognitive state. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
德阳社区年龄大于60岁的老年人 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
Elderly people over 60 years old in Deyang community |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1.肿瘤; 2.脑炎等感染性疾病导致的认知功能障碍; 3.多系统萎缩等炎症性疾病导致的认知功能障碍; 4.已诊断为其他运动障碍退行性疾病的认知功能障碍,如帕金森疾病。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1) cancers; 2) infectious disease such as encephalitis; 3) inflammatory diseases such as multiple sclerosis; 4) any diagnosed movement disorder neurodegenerative disease such as Parkinson's disease |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-01-01 00:00:00至 To 2020-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-01-01 00:00:00 至 To 2021-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
N/A |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
投稿时附件上传 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
uploading attachments to contributors |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过CRF表采集,录入电子管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection through CRF and input all the data into electronic database. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |